【吉林敖东：控股子公司获25个中药配方颗粒上市备案凭证】吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。

金融界2025-06-03

吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2540572332?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-03 15:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540572332","market":"us","top_or_hot":-1,"title":"【吉林敖东：控股子公司获25个中药配方颗粒上市备案凭证】吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。","media":"金融界","content":"<div>\n<p>吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/06/03155750826048.shtml\">网页链接</a>\n\n</div>\n","source":"jinrongjie_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【吉林敖东：控股子公司获25个中药配方颗粒上市备案凭证】吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【吉林敖东：控股子公司获25个中药配方颗粒上市备案凭证】吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-03 15:57 北京时间&nbsp;&nbsp;&nbsp;<a href=https://24h.jrj.com.cn/2025/06/03155750826048.shtml><strong>金融界</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。</p>\n\n<a href=\"https://24h.jrj.com.cn/2025/06/03155750826048.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://24h.jrj.com.cn/2025/06/03155750826048.shtml","article_id":"2540572332","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540572332","pubTimestamp":1748937471,"columns":[],"sourceInfo":{"source_id":"jinrongjie_stock","name":"金融界"},"weMediaInfo":null,"summary":"吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。","collect":0,"end_time":0,"defaultTopTitle":"jrj.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0028":"国家队","BK0074":"参股金融","BK0239":"医药制造","BK0086":"举牌","BK0201":"可转债","BK0188":"融资融券","000623":"吉林敖东","BK0012":"证金概念"},"translate_title":"[Jilin Aodong: The holding subsidiary obtained 25 listing registration certificates of traditional Chinese medicine formula granules] Jilin Aodong announced that the holding subsidiary Yanbian Pharmaceutical Co., Ltd. obtained 25 listing registration certificates of traditional Chinese medicine formula granules, including Jiubing, American ginseng, Huoxiang, fried rice buds, etc. As of the announcement date, Yanbian Pharmaceutical has obtained a total of 525 listing registration certificates. The acquisition of this filing certificate will have a positive impact on the company's expansion of t","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000623":1},"content_text":"吉林敖东公告，控股子公司延边药业获得25个中药配方颗粒上市备案凭证，包括救必应、西洋参、藿香、炒稻芽等。截至公告日，延边药业已累计获得525个上市备案凭证。此次备案凭证的获得将对公司拓展中药配方颗粒业务产生积极影响，增强企业核心竞争力。上述产品的销售情况受市场环境变化等因素影响，存在不确定性，短期内不会对业绩产生重大影响。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2540572332","isCrawlerRequest":true}